XOMA Royalty Closes Acquisition of LAVA Therapeutics

XOMA Royalty Corporation has completed its previously announced acquisition of all outstanding common shares of LAVA Therapeutics N.V. LAVA shareholders received $1.04 in cash per share and a non-transferable contingent value right (CVR), which entitles holders to certain future cash payments. These payments include the right to receive 75% of any net proceeds related to LAVA’s two partnered assets and from any out-license or sale of unpartnered programs, as well as up to approximately $0.23 per CVR, depending on the final determination of certain potential liabilities. Following the completion of the transaction, XOMA Royalty now owns 100% of LAVA’s successor, and public trading of LAVA shares has been suspended with plans to delist from Nasdaq. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580165-en) on November 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)